Drug intelligence / Profile preview

gisadenafil

Development stage: Phase 2
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

Gisadenafil is a phosphodiesterase type 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction. It is structurally and mechanistically related to sildenafil, vardenafil, and tadalafil, acting by inhibiting the enzyme PDE5 to increase levels of cyclic guanosine monophosphate (cGMP), resulting in smooth muscle relaxation and increased blood flow in the corpus cavernosum. This mechanism facilitates penile erection during sexual stimulation. Gisadenafil has been investigated as an oral small molecule therapy for male erectile dysfunction.

Other names: gisadenafil besylate

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on gisadenafil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gisadenafil.

Explore the full profile